Article
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
JCI insight - 20 Aug 2020
Cairns Junmei, Ingle James N, Dudenkov Tanda M, Kalari Krishna R, Carlson Erin E, Na Jie, Buzdar Aman U, Robson Mark E, Ellis Matthew J, Goss Paul E, Shepherd Lois E, Goodnature Barbara, Goetz Matthew P, Weinshilboum Richard M, Li Hu, Bari Mehrab Ghanat, Wang Liewei
Abstract excerpt
Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exemestane, we identified a single nucleotide polymorphism (SNP) in CUB And Sushi multiple domains 1 (CSMD1) associated with breast cancer-free interval, with the variant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.